Leerink Partners Downgrades AbCellera Biologics to Market Perform, Announces $4 Price Target
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Leerink Partners analyst Faisal Khurshid downgrades AbCellera Biologics (NASDAQ:ABCL) from Outperform to Market Perform and announces $4 price target.
Leerink Partners analyst Faisal Khurshid downgrades AbCellera Biologics (NASDAQ:ABCL) from Outperform to Market Perform and announces $4 price target.